Memory and exploratory impairment in mice that lack the Park-2 gene and that over-express the human FTDP-17 mutant Tau

Behavioural Brain Research

Volumn 189, Issue 2, 2008, Pages 350-356

  Navarro, Paloma ^a   Guerrero, Rosa ^a   Gallego, Eva ^a   Avila, Jesus ^a   Luquin, Rosario ^b   Ruiz, Pedro J Garcia ^a   Sanchez, Marina P ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Universidad de Pamplona   (Spain)

Author keywords

FTDP tau mutations; Human tau transgene; Memory alterations; Mouse model; Object recognition task; Park 2 gene deletion; Parkin

Indexed keywords

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; AUTOSOMAL RECESSIVE INHERITANCE; BRAIN CORTEX; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; HIPPOCAMPUS; MEMORY DISORDER; MOTOR PERFORMANCE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PARK 2 GENE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STRIATONIGRAL DEGENERATION; TAU GENE;

AGE FACTORS; ANIMALS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; HUMANS; MALE; MEMORY DISORDERS; MICE; MICE, NEUROLOGIC MUTANTS; MICE, TRANSGENIC; MUTANT PROTEINS; MUTATION, MISSENSE; PSYCHOMOTOR PERFORMANCE; RECOGNITION (PSYCHOLOGY); TAU PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 41149107261     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2008.01.017     Document Type: Article

References (59)

1. Abbas N., Lucking C.B., Ricard S., Durr A., Bonifati V., De Michele G., et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum Mol Genet 8 (1999) 567-574
2. Allen B., Ingram E., Takao M., Smith M.J., Jakes R., Virdee K., et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 22 (2002) 9340-9351
3. Alonso A., Zaidi T., Novak M., Grundke-Iqbal I., and Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA 98 (2001) 6923-6928
4. Arendash G.W., Lewis J., Leighty R.E., McGowan E., Cracchiolo J.-R., Hutton M., et al. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res 1012 (2004) 29-41
5. Arendt T., Bigl V., Arendt A., and Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease. Acta Neuropathol (Berl) 61 (1983) 101-108
6. Bramblett G.T., Goeder M., Jakes R., Merrick S.E., Trojanowski J.Q., and Lee V.M. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 10 (1993) 1089-1099
7. Brecht W.J., Harris F.M., Chang S., Tesseur I., Yu G.Q., Xu Q., et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 24 (2004) 2527-2534
8. Brion J.P., Tremp G., and Octave J.N. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. Am J Pathol 154 (1999) 255-270
9. Duff K., Knight H., Refolo L.M., Sanders S., Yu X., Picciano M., et al. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis 7 (2000) 87-98
10. Feany M.B., and Dickson D.W. Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann Neurol 40 (1996) 139-148
11. Goedert M., Spillantini M.G., Cairns N.J., and Crowther R.A. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8 (1992) 159-168
12. Gomez-Isla T., Price J.L., McKeel Jr. D.W., Morris J.C., Growdon J.H., and Hyman B.T. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16 (1996) 4491-4500
13. Gotz J., Chen F., Barmettler R., and Nitsch R.M. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276 (2001) 529-534
14. Gotz J., Chen F., van Dorpe J., and Nitsch R.M. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ 42 fibrils. Science 293 (2001) 1491-1495
15. Gotz J., Tolnay M., Barmettler R., Chen F., Probst A., and Nitsch R.M. Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. Eur J Neurosci 13 (2001) 2131-2140
16. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., and Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83 (1986) 4913-4917
17. Guerrero R, Navarro P, Gallego E, Avila J, García de Yébenes J, Sanchez, MP. Park2-null/tau transgenic mice reveal an interaction between parkin and tau. J Alzheimers Dis; March 2008.
18. Hattori N., Kitada T., Matsumine H., Asakawa S., Yamamura Y., Yoshino H., et al. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol 44 (1998) 935-941
19. Hayashi S., Wakabayashi K., Ishikawa A., Nagai H., Saito M., Maruyama M., et al. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Dis 15 (2000) 884-888
20. Hutton M., Lendon C.L., and Rizzu P. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393 (1998) 702-705
21. Ikeda M., Shoji M., Kawarai T., Kawarabayashi T., Matsubara E., Murakami T., et al. Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am J Pathol 166 (2005) 521-531
22. Iqbal K., and Grundke-Iqbal I. Discoveries of Tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective. J Alzheimers Dis 9 (2006) 219-242
23. Ishihara T., Hong M., Zhang B., Nakagawa Y., Lee M.K., Trojanowski J.Q., and Lee V.M. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24 (1999) 751-762
24. Itier J.M., Ibanez P., Mena M.A., Abbas N., Cohen-Salmon C., Bohme A., et al. Parkin gene inactivation alters behavior and dopamine neurotransmission in the mouse. Hum Mol Genet 12 (2003) 2277-2291
25. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamuram Y., Minoshima S., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
26. Klein R.L., Dayton R.D., Henderson K.M., and Petrucelli L. Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model. Neurosci Lett 401 (2006) 130-135
27. Layfield R., Cavey J.R., and Lowe J. Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res Rev 2 (2003) 343-356
28. Leroy E., Anastasopoulos D., Konitsiotis S., Laveda C., and Polymeropoulos M.H. Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease. Hum Genet 103 (1998) 424-427
29. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293 (2001) 1487-1491
30. Lim F., Lucas J.J., Gomez-Ramos P., Moran M.A., and Avila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol Cell Neurosci 8 (2001) 702-714
31. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., and Avila J. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J 20 (2001) 27-39
32. Matsumine H., Saito M., and Shimoda-Matsubayashi S. Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 60 (1997) 588-596
33. Menendez J., Rodriguez-Navarro J.A., Solano R.M., Casarejos M.J., Rodal I., Guerrero R., et al. Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein. Hum Mol Genet 15 (2006) 2045-2058
34. Morales B., Martinez A., Gonzalo I., Vidal L., Gomez-Tortosa E., Rabano A., et al. Steele-Richardson-Olszewski syndrome in a patient with a single C212Y mutation in the parkin protein. Mov Dis 17 (2002) 1374-1380
35. Mori H., Kondo T., and Yokochi M. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 51 (1998) 890-892
36. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., and LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24 (2003) 1063-1070
37. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39 (2003) 409-421
38. Pennanen L., Wolfer D.P., Nitsch R.M., and Götz J. Impaired spatial reference memory and increased exploratory behaviour in P301L transgenic mice. Genes Brain Behav 5 (2006) 369-379
39. Petrucelli L., Dickson D., Kehoe K., Taylor J., Snyder H., Grover A., et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 13 (2004) 703-714
40. Petrucelli L.K., and Lockhart P. Tau is a parkin substrate; implications for neurodegenerative disease. Mov Dis 17 (2002) S156
41. Poorkaj P., Bird T.D., and Wijsman E. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 43 (1998) 815-825
42. Sahara N., Murayama M., Mizoroki T., Urushitani M., Imai Y., Takahashi R., et al. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem 94 (2005) 1254-1263
43. Sanchez M.P., Gonzalo I., Avila J., and García de Yébenes J. Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation. J Alzheimers Dis 4 (2002) 399-404
44. SantaCruz KS, Paulson J, Lewis J, Mariash A, Forster C, Guimaraes A, et al. Cell loss and gliosis in a transgenic mouse with regulatable P301L tau overexpression. Poster 840.25 presented at the society for neuroscience meeting, New Orleans, AT.
45. Schindowski K., Bretteville A., Leroy K., Bégard S., Brion J.P., Hamdane M., and Buée L. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169 (2006) 599-616
46. Scott S.A., DeKosky S.T., Sparks D.L., Knox C.A., and Scheff S.W. Amygdala cell loss and atrophy in Alzheimer's disease. Ann Neurol 32 (1992) 555-563
47. Shimura H., Hattori N., and Kubo S. Familial Parkinson disease gene product, parkin, is an ubiquitin-protein ligase. Nat Genet 25 (2000) 302-305
48. Shimura H., Schwartz D., Gygi S.P., and Kosik K.S. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 279 (2004) 4869-4876
49. Spillantini M.G. Tau and Parkinson disease. J Am Med Assoc 286 (2001) 2324-2326
50. Spillantini M.G., Bird T.D., and Ghetti B. Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol 8 (1998) 387-402
51. Spires T.L., and Hyman B.T. Transgenic models of Alzheimer's disease: learning from animals. Neuro Rx 2 (2005) 423-437
52. Stanford P.M., Brooks W.S., and Teber E.T. Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. J Neurol 251 (2004) 1098-1104
53. Tanemura K., Murayama M., Akagi T., Hashikawa T., Tominaga T., Ichikawa M., et al. Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J Neurosci 22 (2002) 133-141
54. Tatebayashi Y., Miyasaka T., Chui D.H., Akagi T., Mishima K., Iwasaki K., et al. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc Natl Acad Sci USA 99 (2002) 13896-13901
55. van Leeuwen F.W., Hol E.M., and Fischer D.F. Frameshift proteins in Alzheimer's disease and in other conformational disorders: time for the ubiquitin-proteasome system. J Alzheimers Dis 9 (2006) 319-325
56. van De Warrenburg B.P., Lammens M., and Lucking C.B. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56 (2001) 555-557
57. von Coelln R., Dawson V.L., and Dawson T.M. Parkin-associated Parkinson's disease. Cell Tissue Res 318 (2004) 175-184
58. West A., Lincoln S., Lucking C.B., Nicholl D., Bonifati V., Rawal N., et al. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility on Parkinson's Disease. Complex relationship between Parkin mutations and Parkinson disease. Am J Med Genet 114 (2002) 584-591
59. Wszolek Z.K., Pfeiffer R.F., Tsuboi Y., Uitti R.J., McComb R.D., Stoessl A.J., et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62 (2004) 1619-1622